Loading
A phase 3 trial of Recombinant human endostatin in Non-small-cell lung cancer, run by Shanghai Jiao Tong University School of Medicine, completed.
Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC) is a phase 3 interventional study registered as NCT01124253 by Shanghai Jiao Tong University School of Medicine, with 250 participants recorded, started 2007-07 and reaching its primary completion in 2009-10. Interventions recorded: recombinant human endostatin. Conditions recorded: Non-small Cell Lung Cancer.
Linked to the drug Recombinant human endostatin because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Recombinant human endostatin, Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Recombinant human endostatin, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.